



12-16-2016

12:45 - 14:15	Pfizer - Optimizing the Continuum of Care in Renal Cell Carcinoma	Hall 404
---------------	---	----------

12:45 - 12:55	Welcome and Introduction	
---------------	--------------------------	--

12:55 - 13:15	The evolving landscape in Advanced Renal Cell Carcinoma: Recent advances and future outlook	
---------------	---	--

13:15 - 13:35	New Advances in Adjuvant Renal Cell Carcinoma: how will the landscape change?	
---------------	---	--

13:35 - 14:10	Tumor Board: Management of High-Risk Renal Cell Carcinoma – Asian perspective	
---------------	---	--

14:10 - 14:15	Conclusions / Clinical perspectives	
---------------	-------------------------------------	--

12:45 - 14:15	Merck - The role of immune checkpoint inhibitors in gastric cancer	Summit 2
---------------	--	----------

12:45 - 12:55	Welcome & Introduction	
---------------	------------------------	--

12:55 - 13:15	Introduction to immuno-oncology	
---------------	---------------------------------	--

13:15 - 13:40	Immune checkpoint inhibitors in gastric cancer. Part one: Second- and third-line treatment of gastric cancer	
---------------	--	--

13:40 - 14:05	Immune checkpoint inhibitors in gastric cancer. Part two: First-line treatment of gastric cancer	
---------------	--	--

14:05 - 14:15	Q&A / Faculty discussion / closing comments	
---------------	---	--



12:45 - 14:15	Roche - Advances in Targeted Therapy in Maximising the Care of Patients with Lung Cancer	Hall 336
12:45 - 12:55	Overview: personalised healthcare and the continued critical role of biomarkers in NSCLC treatment	
12:55 - 13:15	Optimising EGFR TKI therapy: combination therapies in patients with EGFR mutation	
13:15 - 13:35	Advances in ALK therapy: changing the treatment landscape	
13:35 - 13:55	Cancer immunotherapy: role of biomarkers in treatment paradigm	
13:55 - 14:15	Q&A session	

12-17-2016

12:45 - 14:15	Springer Healthcare IME - Advances in gastric cancer care	Hall 404
12:45 - 12:50	Welcome and Introduction	
12:50 - 13:20	The surgical treatment pathway	
13:20 - 13:45	Optimising patient care in metastatic gastric cancer	
13:45 - 14:10	Future directions in metastatic gastric cancer	
14:10 - 14:15	Summary and Closing Remarks	



12:45 - 14:15	MSD - Advances in NSCLC Treatment; Immuno-Oncology Update	Hall 405
---------------	---	----------

12:45 - 12:55	Welcome & Introduction	
---------------	------------------------	--

12:55 - 13:15	Update: 1st line-NSCLC (focus on KN 024 and 001)	
---------------	--	--

13:15 - 13:35	Update: Further lines-NSCLC (focus on KN 010 and 001)	
---------------	--	--

13:35 - 13:55	Role of biomarker in NSCLC: PD-L1	
---------------	-----------------------------------	--

13:55 - 14:15	Going forward in a PD-1 (I-O) world	
---------------	-------------------------------------	--

12:45 - 14:15	Bristol-Myers Squibb - Immuno-Oncology At the Forefront of Cancer Treatment: Emerging Data in Summit Lung Cancer, Genitourinary Cancers, and Melanoma	2
---------------	---	---

12:45 - 12:55	Welcome and Introductions	
---------------	---------------------------	--

12:55 - 13:10	Clinical Update for I-O in Melanoma	
---------------	-------------------------------------	--

13:10 - 13:35	Clinical Update for I-O in Lung Cancers	
---------------	---	--

13:35 - 13:55	Clinical Update for I-O in RCC and Bladder Cancers	
---------------	--	--

13:55 - 14:00	Close & Outlook	
---------------	-----------------	--



12:45 - 14:15	Roche - Genomic profiling: The foundation for personalised cancer care	Hall 336
12:45 - 12:50	Overview: Capturing the essence of genomic profiling in oncology	
12:50 - 13:05	Demystifying genomic profiling: Why is it a prerequisite for personalised care?	
13:05 - 13:25	What will it take for genomic profiling to become mainstream?	
13:25 - 13:45	An oncologist's bid to personalise patient care with genomic profiling	
13:45 - 14:05	Using genomic profiling in emerging Asian economies and what the future holds	
14:05 - 14:15	Panel discussion	
18:00 - 19:30	Boehringer Ingelheim International GmbH - NSCLC treatment updates: Connecting evidence to clinical practice	Summit 2
18:00 - 18:10	Welcome, introductions and opening presentation	
18:10 - 18:35	Treatment choice in EGFR mutation-positive NSCLC (presentation, case studies and panel discussion) First-line Irreversible ErbB Family blockade	
18:35 - 18:45	First-line treatment resistance: mechanisms and treatment implications	
18:45 - 18:55	Panel discussion: Discussing the evidence	
18:55 - 19:00	ErbB Family blockade in advanced squamous cell carcinoma (SqCC): clinical insights (presentation, case studies and panel discussion)	

12-18-2016



12:45 - 14:15	MSD - Immuno-Oncology Update (Pan-tumour) Head & Neck, Bladder, GI	Hall 405
12:45 - 12:55	Welcome & Introduction	
12:55 - 13:15	Immuno-Oncology Update in Head & Neck	
13:15 - 13:35	Immuno-Oncology Update in Bladder Cancer	
13:35 - 13:55	Immuno-Oncology Update in GI	
13:55 - 14:15	Panel discussion	
12:45 - 14:15	Bristol-Myers Squibb - Advances in Immuno-Oncology Research for Gastrointestinal Cancers	Summit 2
12:45 - 12:50	Welcome & Introductions	
12:50 - 13:05	Harnessing the Immune System in GI Cancer Research	
13:05 - 13:25	Immune Checkpoint Inhibition: Emerging Research and Future Directions in Gastric Cancers	
13:25 - 13:45	Evaluating the Potential of Immune Checkpoint Inhibition in Esophageal Cancers	
13:45 - 14:05	dMMR/MSI-High: Addressing Unmet Needs through Immuno-Oncology	
14:05 - 14:15	Q&A and Meeting Close	



12:45 - 14:15	AstraZeneca - Advancing Personalized Therapy for Non-Small Cell Lung Cancer in Asia	Hall 336
12:45 - 13:35	Personalized Medicine in Non- Small Cell Lung Cancer Treatment	
13:35 - 13:55	AURA trial: Korean subpopulation analysis	
13:55 - 14:15	Q&A	